Carmen Jeronimo

List of Publications by Year
in descending order

295	11,841	26630	43889
papers	citations	56 h-index	91 g-index

305	305	305	14776
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantitation of GSTP1 Methylation in Non-neoplastic Prostatic Tissue and Organ-Confined Prostate Adenocarcinoma. Journal of the National Cancer Institute, 2001, 93, 1747-1752.	6.3	281
2	The timeline of epigenetic drug discovery: from reality to dreams. Clinical Epigenetics, 2019, 11, 174.	4.1	275
3	Human cancer cell antiproliferative and antioxidant activities of Juglans regia L.. Food and Chemical Toxicology, 2010, 48, 441-447.	3.6	243
4	Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Research, 2002, 62, 371-5.	0.9	240
5	P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation. Clinical Cancer Research, 2005, 11, 5869-5877.	7.0	236
6	A Quantitative Promoter Methylation Profile of Prostate Cancer. Clinical Cancer Research, 2004, 10, 8472-8478.	7.0	234
7	Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects. Journal of Clinical Oncology, 2005, 23, 6569-6575.	1.6	227
8	TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN Lesions. Neoplasia, 2006, 8, 826-832.	5.3	225
9	Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene, 2001, 20, 5195-5198.	5.9	220
10	Detection of Aberrant Methylation of Four Genes in Plasma DNA for the Detection of Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4262-4269.	1.6	219
11	Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer. Cancer Research, 2004, 64, 5511-5517.	0.9	218
12	Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology, 2002, 60, 1131-1135.	1.0	196
13	Epigenetics in Prostate Cancer: Biologic and Clinical Relevance. European Urology, 2011, 60, 753-766.	1.9	187
14	Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics, 2015, 7, 1003-1015.	2.1	173
15	Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2008, 14, 97-107.	7.0	163
16	BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology, 2004, 17, 1359-1363.	5.5	161
17	Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples. Clinical Cancer Research, 2010, 16, 5842-5851.	7.0	155
18	Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome. Cancer Research, 2008, 68, 2661-2670.	0.9	131

#	Article	IF	Citations
19	High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients. Clinical Cancer Research, 2007, 13, 6122-6129.	7.0	122
20	Molecular Detection of Prostate Cancer: A Role for GSTP1 Hypermethylation. European Urology, 2004, 46, 660-669.	1.9	119
21	QuantitativeRARÎ²2Hypermethylation. Clinical Cancer Research, 2004, 10, 4010-4014.	7.0	117
22	Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications. Genes, 2018, 9, 429.	2.4	108
23	DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types. Cells, 2020, 9, 624.	4.1	108
24	Integrative epigenetic taxonomy of primary prostate cancer. Nature Communications, 2018, 9, 4900.	12.8	107
25	Biological activities of Portuguese propolis: Protection against free radical-induced erythrocyte damage and inhibition of human renal cancer cell growth in vitro. Food and Chemical Toxicology, 2011, 49, 86-92.	3.6	106
26	TCF21andPCDH17methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics, 2011, 6, 1120-1130.	2.7	99
27	Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic. International Journal of Molecular Sciences, 2019, 20, 258.	4.1	93
28	MicroRNA-375 plays a dual role in prostate carcinogenesis. Clinical Epigenetics, 2015, 7, 42.	4.1	88
29	Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Frontiers in Genetics, 2018, 9, 427.	2.3	88
30	Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis. Molecular Cancer Research, 2006, 4, 1-8.	3.4	85
31	Detection of Promoter Hypermethylation in Salivary Rinses as a Biomarker for Head and Neck Squamous Cell Carcinoma Surveillance. Clinical Cancer Research, 2011, 17, 4782-4789.	7.0	84
32	Epigenetic biomarkers in urological tumors: A systematic review. Cancer Letters, 2014, 342, 264-274.	7.2	82
33	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes and Control, 2015, 26, 1603-1616.	1.8	77
34	Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocrine-Related Cancer, 2014, 21, 51-61.	3.1	76
35	Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine. British Journal of Cancer, 2019, 121, 857-868.	6.4	74
36	FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes and Cancer, 2012, 51, 240-249.	2.8	73

#	Article	IF	Citations
37	Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells, 2019, 8, 1637.	4.1	73
38	In-air production of 3D co-culture tumor spheroid hydrogels for expedited drug screening. Acta Biomaterialia, 2019, 94, 392-409.	8.3	72
39	MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. British Journal of Cancer, 2013, 109, 2646-2653.	6.4	71
40	Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer Letters, 2017, 385, 150-159.	7.2	70
41	Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction. Frontiers in Oncology, 2019, 9, 900.	2.8	69
42	SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3. Oncotarget, 2015, 6, 13644-13657.	1.8	69
43	Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium. Oncotarget, 2016, 7, 1144-1154.	1.8	69
44	Epigenetic modulators as therapeutic targets in prostate cancer. Clinical Epigenetics, 2016, 8, 98.	4.1	68
45	The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors. Genes, 2018, 9, 552.	2.4	68
46	Expression and functionality of histone H2A variants in cancer. Oncotarget, 2014, 5, 3428-3443.	1.8	66
47	MT1G Hypermethylation Is Associated with Higher Tumor Stage in Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1274-1278.	2.5	65
48	8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects. Clinical Cancer Research, 2006, 12, 3961-3970.	7.0	65
49	MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors. Molecular Cancer, 2017, 16, 26.	19.2	64
50	GCâ€MS metabolomicsâ€based approach for the identification of a potential VOCâ€biomarker panel in the urine of renal cell carcinoma patients. Journal of Cellular and Molecular Medicine, 2017, 21, 2092-2105.	3.6	64
51	Deleted in Colorectal Cancer Is a Putative Conditional Tumor-Suppressor Gene Inactivated by Promoter Hypermethylation in Head and Neck Squamous Cell Carcinoma. Cancer Research, 2006, 66, 9401-9407.	0.9	63
52	Molecular Subtyping of Primary Prostate Cancer Reveals Specific and Shared Target Genes of Different ETS Rearrangements. Neoplasia, 2012, 14, 600-IN15.	5.3	63
53	Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer. BMC Genomics, 2013, 14, 898.	2.8	62
54	Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems. International Journal of Cancer, 2016, 139, 256-268.	5.1	62

#	Article	IF	Citations
55	Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists. Human Pathology, 2018, 82, 113-124.	2.0	62
56	Frequent 14-3-3 Ïƒ Promoter Methylation in Benign and Malignant Prostate Lesions. DNA and Cell Biology, 2005, 24, 264-269.	1.9	60
57	Quantitative hypermethylation of NMDAR2B in human gastric cancer. International Journal of Cancer, 2007, 121, 1994-2000.	5.1	60
58	VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer. Cancers, 2020, 12, 771.	3.7	59
59	Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer, 2007, 7, 133.	2.6	58
60	Decoding the usefulness of non-coding RNAs as breast cancer markers. Journal of Translational Medicine, 2016, 14, 265.	4.4	58
61	Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2572-81.	7.1	56
62	m6A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance. Journal of Translational Medicine, 2019, 17, 79.	4.4	55
63	Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. Journal of Molecular Medicine, 2006, 84, 911-918.	3.9	54
64	Analysis of volatile human urinary metabolome by solid-phase microextraction in combination with gas chromatographyâ€“mass spectrometry for biomarker discovery: Application in a pilot study to discriminate patients with renal cell carcinoma. European Journal of Cancer, 2014, 50, 1993-2002.	2.8	54
65	Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clinical Cancer Research, 2003, 9, 3413-7.	7.0	54
66	A Rapid and Simple Procedure for the Establishment of Human Normal and Cancer Renal Primary Cell Cultures from Surgical Specimens. PLoS ONE, 2011, 6, e19337.	2.5	53
67	Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene, 2003, 22, 6954-6958.	5.9	52
68	Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication. Epigenetics, 2015, 10, 1033-1043.	2.7	51
69	Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. Journal of Clinical Pathology, 2004, 57, 872-876.	2.0	50
70	Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS. Scientific Reports, 2018, 8, 5539.	3.3	50
71	Relative Copy Number Gain of MYC in Diagnostic Needle Biopsies is an Independent Prognostic Factor for Prostate Cancer Patients. European Urology, 2007, 52, 116-125.	1.9	49
72	Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing. Epigenetics, 2013, 8, 548-558.	2.7	49

#	Article	IF	Citations
73	Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. Journal of the American Academy of Dermatology, 2000, 43, 991-1000.	1.2	48
74	Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. Journal of Clinical Pathology, 2003, 56, 52-55.	2.0	48
75	Epigenetic Markers for Molecular Detection of Prostate Cancer. Disease Markers, 2007, 23, 31-41.	1.3	48
76	Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer. Journal of Urology, 2008, 179, 743-747.	0.4	48
77	Anti-neoplastic properties of hydralazine in prostate cancer. Oncotarget, 2014, 5, 5950-5964.	1.8	48
78	Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer. Journal of Hematology and Oncology, 2017, 10, 43.	17.0	48
79	MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis. Cell Death and Disease, 2018, 9, 167.	6.3	48
80	Anti-Tumoral Effect of the Non-Nucleoside DNMT Inhibitor RG108 in Human Prostate Cancer Cells. Current Pharmaceutical Design, 2014, 20, 1803-1811.	1.9	48
81	Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Research and Treatment, 2008, 109, 27-34.	2.5	47
82	Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. European Journal of Cancer, 2014, 50, 226-233.	2.8	47
83	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	2.7	47
84	Germ cell tumour subtypes display differential expression of microRNA371a-3p. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170338.	4.0	46
85	A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA. Journal of Clinical Medicine, 2018, 7, 420.	2.4	46
86	Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. Oncotarget, 2016, 7, 53018-53028.	1.8	46
87	Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer. Oncotarget, 2013, 4, 1673-1685.	1.8	45
88	Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes and Cancer, 2006, 45, 154-163.	2.8	44
89	External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1804-1812.	2.5	44
90	Cocaine-induced kidney toxicity: an in vitro study using primary cultured human proximal tubular epithelial cells. Archives of Toxicology, 2012, 86, 249-261.	4.2	43

#	Article	IF	Citations
91	Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women. Cancers, 2018, 10, 357.	3.7	43
92	Green tea: A promising anticancer agent for renal cell carcinoma. Food Chemistry, 2010, 122, 49-54.	8.2	42
93	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Medicine, 2016, 14, 66.	5.5	42
94	Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. Cancers, 2019, 11, 1535.	3.7	42
95	I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 445-50.	2.5	42
96	Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes and Cancer, 2010, 49, 935-947.	2.8	41
97	Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. EBioMedicine, 2019, 44, 431-438.	6.1	41
98	High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 161.e7-161.e17.	1.6	41
99	Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate, 2013, 73, 763-769.	2.3	40
100	DNA methylation profiling as a tool for testicular germ cell tumors subtyping. Epigenomics, 2018, 10, 1511-1523.	2.1	40
101	Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel. Clinical Epigenetics, 2019, 11, 175.	4.1	40
102	A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97. Clinical Epigenetics, 2018, 10, 40.	4.1	39
103	A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway. Journal of Translational Medicine, 2018, 16, 45.	4.4	39
104	Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate, 2008, 68, 418-426.	2.3	38
105	Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 956-965.	4.9	37
106	The epigenetics of testicular germ cell tumors: looking for novel disease biomarkers. Epigenomics, 2017, 9, 155-169.	2.1	37
107	Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies. Journal of Clinical Medicine, 2019, 8, 1500.	2.4	37
108	Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives. Cancers, 2020, 12, 1601.	3.7	37

#	Article	IF	Citations
109	Cysteine-Rich Secretory Protein-3 (CRISP3) Is Strongly Up-Regulated in Prostate Carcinomas with the TMPRSS2-ERG Fusion Gene. PLoS ONE, 2011, 6, e22317.	2.5	36
110	Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes. Breast Cancer Research and Treatment, 2013, 138, 37-45.	2.5	36
111	Novel 5â€² Fusion Partners of ETV1 and ETV4 in Prostate Cancer. Neoplasia, 2013, 15, 720-IN6.	5.3	36
112	Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma. Scientific Reports, 2016, 6, 37275.	3.3	36
113	Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cellular Oncology, 2008, 30, 389-95.	1.9	36
114	Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer. Frontiers in Genetics, 2019, 10, 815.	2.3	35
115	DNA Methylation as a Therapeutic Target for Bladder Cancer. Cells, 2020, 9, 1850.	4.1	35
116	Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics, 2010, 5, 343-351.	2.7	34
117	Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients. PLoS ONE, 2015, 10, e0132728.	2.5	34
118	MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples. Journal of Experimental and Clinical Cancer Research, 2020, 39, 98.	8.6	34
119	Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy. Clinical Epigenetics, 2021, 13, 63.	4.1	34
120	Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer. International Journal of Molecular Sciences, 2019, 20, 297.	4.1	33
121	JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma. Cell Death and Disease, 2020, 11, 1068.	6.3	33
122	ssDNA-Binding Protein 2 Is Frequently Hypermethylated and Suppresses Cell Growth in Human Prostate Cancer. Clinical Cancer Research, 2008, 14, 3754-3760.	7.0	32
123	Volatile metabolomic signature of bladder cancer cell lines based on gas chromatographyâ€“mass spectrometry. Metabolomics, 2018, 14, 62.	3.0	32
124	Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. European Journal of Cancer, 2011, 47, 1106-1114.	2.8	31
125	High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Research and Treatment, 2011, 129, 1-9.	2.5	31
126	The Epigenetics of Renal Cell Tumors: from Biology to Biomarkers. Frontiers in Genetics, 2012, 3, 94.	2.3	29

#	Article	IF	Citations
127	The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelialâ€“mesenchymal transition in mammary epithelial and in breast cancer cells. Cancer Letters, 2017, 396, 42-52.	7.2	29
128	Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. Translational Research, 2017, 180, 1-11.	5.0	29
129	Targeting DNA Methyltranferases in Urological Tumors. Frontiers in Pharmacology, 2018, 9, 366.	3.5	29
130	Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2127-2137.	2.5	28
131	Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations. PLoS ONE, 2013, 8, e58206.	2.5	28
132	Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. International Journal of Cancer, 2004, 108, 592-595.	5.1	27
133	Overexpression of circulating MiR-30b-5p identifies advanced breast cancer. Journal of Translational Medicine, 2019, 17, 435.	4.4	27
134	Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary TERT Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer. Cancers, 2020, 12, 3541.	3.7	27
135	Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics. Metabolites, 2021, 11, 199.	2.9	27
136	Genome-Wide DNA Methylation Profiling of Esophageal Squamous Cell Carcinoma from Global High-Incidence Regions Identifies Crucial Genes and Potential Cancer Markers. Cancer Research, 2021, 81, 2612-2624.	0.9	27
137	The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. Journal of Experimental and Clinical Cancer Research, 2021, 40, 268.	8.6	27
138	Immunophenotyping by flow cytometry of fine needle aspirates in the diagnosis of lymphoproliferative disorders: A retrospective study. , 1999, 13, 224-228.		26
139	Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors. PLoS ONE, 2015, 10, e0134969.	2.5	26
140	The Role of DNA/Histone Modifying Enzymes and Chromatin Remodeling Complexes in Testicular Germ Cell Tumors. Cancers, 2019, 11, 6.	3.7	26
141	Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation. Cells, 2020, 9, 1053.	4.1	26
142	Relative 8q gain predicts diseaseâ€specific survival irrespective of the TMPRSS2â€ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes and Cancer, 2011, 50, 662-671.	2.8	24
143	XIST-Promoter Demethylation as Tissue Biomarker for Testicular Germ Cell Tumors and Spermatogenesis Quality. Cancers, 2019, 11, 1385.	3.7	24
144	Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7427.	4.1	24

#	Article	IF	Citations
145	New findings on urinary prostate cancer metabolome through combined GCâ€“MS and 1H NMR analytical platforms. Metabolomics, 2020, 16, 70.	3.0	24
146	CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. Modern Pathology, 2009, 22, 744-752.	5.5	23
147	Epigenetic regulation of <scp>EFEMP</scp>1 in prostate cancer: biological relevance and clinical potential. Journal of Cellular and Molecular Medicine, 2014, 18, 2287-2297.	3.6	23
148	Pathologic Findings in Prophylactic and Nonprophylactic Hysterectomy Specimens of Patients With Lynch Syndrome. American Journal of Surgical Pathology, 2016, 40, 1177-1191.	3.7	23
149	Urinary Volatilomics Unveils a Candidate Biomarker Panel for Noninvasive Detection of Clear Cell Renal Cell Carcinoma. Journal of Proteome Research, 2021, 20, 3068-3077.	3.7	23
150	Methylation-Specific PCR. Methods in Molecular Biology, 2018, 1708, 447-472.	0.9	22
151	GC-MS-Based Endometabolome Analysis Differentiates Prostate Cancer from Normal Prostate Cells. Metabolites, 2018, 8, 23.	2.9	22
152	The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance. Genes, 2019, 10, 927.	2.4	22
153	MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease. British Journal of Cancer, 2006, 95, 752-756.	6.4	21
154	Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients. Clinical Epigenetics, 2018, 10, 132.	4.1	21
155	Sirtuinsâ€™ Deregulation in Bladder Cancer: SIRT7 Is Implicated in Tumor Progression through Epithelial to Mesenchymal Transition Promotion. Cancers, 2020, 12, 1066.	3.7	21
156	Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances. Cancers, 2021, 13, 1529.	3.7	21
157	Potential Downstream Target Genes of Aberrant ETS Transcription Factors Are Differentially Affected in Ewingâ€™s Sarcoma and Prostate Carcinoma. PLoS ONE, 2012, 7, e49819.	2.5	21
158	Altered Expression of Histone Deacetylases in Cancer. Critical Reviews in Oncogenesis, 2015, 20, 19-34.	0.4	21
159	The role of OncoSnoRNAs and Ribosomal RNA 2â€™-O-methylation in Cancer. RNA Biology, 2021, 18, 61-74.	3.1	21
160	Deciphering the function of non-coding RNAs in prostate cancer. Cancer and Metastasis Reviews, 2016, 35, 235-262.	5.9	20
161	Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel. Journal of Translational Medicine, 2017, 15, 149.	4.4	20
162	Protein phosphatase 1 in tumorigenesis: is it worth a closer look?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188433.	7.4	20

#	Article	IF	Citations
163	Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors. Cancers, 2020, 12, 2903.	3.7	20
164	Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?. Pharmaceutics, 2020, 12, 410.	4.5	20
165	Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes. Journal of Personalized Medicine, 2021, 11, 996.	2.5	20
166	Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Molecular Cancer, 2006, 5, 33.	19.2	19
167	<scp>FOXA</scp>1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. Molecular Oncology, 2018, 12, 1884-1894.	4.6	19
168	Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of â€˜epidrugsâ€™. Epigenetics, 2021, 16, 353-372.	2.7	19
169	Positive Correlation of Tissue Inhibitor of Metalloproteinase-3 and Death-Associated Protein Kinase Hypermethylation in Head and Neck Squamous Cell Carcinoma. Laryngoscope, 2007, 117, 1376-1380.	2.0	18
170	MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma. British Journal of Cancer, 2017, 116, 634-639.	6.4	18
171	Epigenetics in endometrial carcinogenesis â€“ part 2: histone modifications, chromatin remodeling and noncoding RNAs. Epigenomics, 2017, 9, 873-892.	2.1	18
172	SETDB2 and RIOX2 are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization. Epigenetics, 2017, 12, 1057-1064.	2.7	18
173	Positioning Europe for the EPITRANSCRIPTOMICS challenge. RNA Biology, 2018, 15, 1-3.	3.1	18
174	The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma. Genes, 2019, 10, 264.	2.4	18
175	Expression of EMT-Related Genes CAMK2N1 and WNT5A is increased in Locally Invasive and Metastatic Prostate Cancer. Journal of Cancer, 2019, 10, 5915-5925.	2.5	18
176	A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers. Cancers, 2020, 12, 2017.	3.7	18
177	Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer. Communications Biology, 2021, 4, 119.	4.4	18
178	Expression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 379-385.	2.8	17
179	Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer, 2010, 10, 470.	2.6	17
180	Epigenetics in endometrial carcinogenesis â€“ part 1: DNA methylation. Epigenomics, 2017, 9, 737-755.	2.1	17

#	Article	IF	Citations
181	Epigenetic mechanisms underlying prostate cancer radioresistance. Clinical Epigenetics, 2021, 13, 125.	4.1	17
182	Evidence of psychological and biological effects of structured Mindfulnessâ€Based Interventions for cancer patients and survivors: A metaâ€review. Psycho-Oncology, 2021, 30, 1836-1848.	2.3	17
183	Basal Cell Carcinoma-Like Epidermal Changes Overlying Dermatofibromas Often Reveal Loss of Heterozygosity in the PTCH Gene. Journal of Investigative Dermatology, 1999, 113, 279-280.	0.7	16
184	Deregulation of <scp>PAX</scp>2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis. Journal of Cellular and Molecular Medicine, 2013, 17, 1048-1058.	3.6	16
185	Testicular Germ Cell Tumors Go Epigenetics: Will miR-371a-3p Replace Classical Serum Biomarkers?. European Urology, 2017, 71, 221-222.	1.9	16
186	Influence of HOTAIR rs920778 and rs12826786 genetic variants on prostate cancer risk and progression-free survival. Biomarkers in Medicine, 2018, 12, 257-264.	1.4	16
187	GC-MS Metabolomics Reveals Distinct Profiles of Low- and High-Grade Bladder Cancer Cultured Cells. Metabolites, 2019, 9, 18.	2.9	15
188	Targeting the Immune system and Epigenetic Landscape of Urological Tumors. International Journal of Molecular Sciences, 2020, 21, 829.	4.1	15
189	Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Molecular Oncology, 2021, 15, 846-865.	4.6	15
190	LiKidMiRs: A ddPCR-Based Panel of 4 Circulating miRNAs for Detection of Renal Cell Carcinoma. Cancers, 2022, 14, 858.	3.7	15
191	NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. Genes Chromosomes and Cancer, 2016, 55, 365-374.	2.8	14
192	p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome. Andrology, 2020, 8, 1233-1242.	3.5	14
193	The metabolic landscape of urological cancers: New therapeutic perspectives. Cancer Letters, 2020, 477, 76-87.	7.2	14
194	Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation. Cancers, 2021, 13, 2101.	3.7	14
195	Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. Cancers, 2021, 13, 2848.	3.7	14
196	Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review). Oncology Reports, 2019, 41, 1431-1438.	2.6	13
197	Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype. Cancer Cell International, 2019, 19, 112.	4.1	13
198	The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer. Pharmacological Research, 2020, 161, 105145.	7.1	13

#	Article	IF	Citations
199	Liquid Biopsies in the Clinical Management of Germ Cell Tumor Patients: State-of-the-Art and Future Directions. International Journal of Molecular Sciences, 2021, 22, 2654.	4.1	13
200	Secreted Extracellular Vesicle Molecular Cargo as a Novel Liquid Biopsy Diagnostics of Central Nervous System Diseases. International Journal of Molecular Sciences, 2021, 22, 3267.	4.1	13
201	Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples. Clinical Epigenetics, 2021, 13, 70.	4.1	13
202	Functional and Epigenetic Characterization of the KRT19 Gene in Renal Cell Neoplasms. DNA and Cell Biology, 2011, 30, 85-90.	1.9	12
203	New insights on chromatin modifiers and histone postâ€translational modifications in renal cell tumours. European Journal of Clinical Investigation, 2015, 45, 16-24.	3.4	12
204	Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs. Cancers, 2020, 12, 2214.	3.7	12
205	Protein Aggregation Patterns Inform about Breast Cancer Response to Antiestrogens and Reveal the RNA Ligase RTCB as Mediator of Acquired Tamoxifen Resistance. Cancers, 2021, 13, 3195.	3.7	12
206	Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment. Drug Discovery Today, 2021, 26, 2680-2698.	6.4	12
207	Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder. Molecular Carcinogenesis, 2015, 54, 523-531.	2.7	11
208	A DNA methylation-based test for esophageal cancer detection. Biomarker Research, 2020, 8, 68.	6.8	11
209	Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression. Journal of Translational Medicine, 2020, 18, 303.	4.4	11
210	Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. Pharmaceuticals, 2021, 14, 670.	3.8	11
211	Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements. Oncoscience, 2015, 2, 497-507.	2.2	11
212	Comprehensive Metabolomics and Lipidomics Profiling of Prostate Cancer Tissue Reveals Metabolic Dysregulations Associated with Disease Development. Journal of Proteome Research, 2021, , .	3.7	11
213	DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients. Frontiers in Oncology, 0, 12, .	2.8	11
214	DNA Methylation Markers for Prostate Cancer with a Stem Cell Twist. Cancer Prevention Research, 2010, 3, 1053-1055.	1.5	10
215	Behavior of prostate cancer cells in a nanohydroxyapatite/collagen bone scaffold. Journal of Biomedical Materials Research - Part A, 2017, 105, 2035-2046.	4.0	10
216	Oncology research in late twentieth century and turn of the century Portugal: a scientometric approach to its institutional and semantic dimensions. Scientometrics, 2017, 113, 867-888.	3.0	10

#	Article	IF	Citations
217	Mesenchymal Stem Cells Relevance in Multicellular Bioengineered 3D In Vitro Tumor Models. Biotechnology Journal, 2017, 12, 1700079.	3.5	10
218	Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies. Expert Review of Molecular Diagnostics, 2019, 19, 367-375.	3.1	10
219	MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges. European Urology, 2019, 75, 251-252.	1.9	10
220	Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest. Pharmaceutics, 2021, 13, 73.	4.5	10
221	Methylation-Based Biomarkers for Early Detection of Urological Cancer. Critical Reviews in Oncogenesis, 2007, 13, 265-282.	0.4	10
222	Downregulation of m⁶A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness. Molecular Oncology, 2022, 16, 1841-1856.	4.6	10
223	From Therapy Resistance to Targeted Therapies in Prostate Cancer. Frontiers in Oncology, 2022, 12, .	2.8	10
224	The role of pathology in the management of patients with endometrial carcinoma. Future Oncology, 2017, 13, 1003-1020.	2.4	9
225	Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 347-352.	2.8	9
226	Differential expression of DNA methyltransferases and demethylases among the various testicular germ cell tumor subtypes. Epigenomics, 2020, 12, 1579-1592.	2.1	9
227	Volatilomics Reveals Potential Biomarkers for Identification of Renal Cell Carcinoma: An In Vitro Approach. Metabolites, 2020, 10, 174.	2.9	9
228	Stress in Metastatic Breast Cancer: To the Bone and Beyond. Cancers, 2022, 14, 1881.	3.7	9
229	G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models. Biomedicine and Pharmacotherapy, 2022, 150, 113031.	5.6	9
230	Toxic effects of selenium inhalation: acute damage of the respiratory system of mice. Human and Experimental Toxicology, 2003, 22, 551-557.	2.2	8
231	Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers. Expert Review of Molecular Diagnostics, 2012, 12, 871-878.	3.1	8
232	Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 1349-1358.	2.4	8
233	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somaticTMPRSS2:ERGfusion status. Human Molecular Genetics, 2016, 25, ddw349.	2.9	8
234	Unveiling the World of Circulating and Exosomal microRNAs in Renal Cell Carcinoma. Cancers, 2021, 13, 5252.	3.7	8

#	Article	IF	Citations
235	Application of Proteogenomics to Urine Analysis towards the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study. Cancers, 2022, 14, 2001.	3.7	8
236	Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 443-452.	2.8	7
237	Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes. International Journal of Molecular Sciences, 2020, 21, 3522.	4.1	7
238	A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions. Journal of Clinical Medicine, 2020, 9, 605.	2.4	7
239	Performance of DNA methylationâ€based biomarkers in the cervical cancer screening program of northern Portugal: A feasibility study. International Journal of Cancer, 2021, 149, 1916-1925.	5.1	7
240	RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2020, 9, 1000.	2.4	6
241	Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer. Biomedicines, 2021, 9, 976.	3.2	6
242	Bridging the Gaps between Circulating Tumor Cells and DNA Methylation in Prostate Cancer. Cancers, 2021, 13, 4209.	3.7	6
243	DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?. Cancers, 2022, 14, 2918.	3.7	6
244	Endometrial Carcinoma in Portugal. International Journal of Gynecological Pathology, 2015, 34, 159-168.	1.4	5
245	Comprehensive Analysis of Secreted Protein, Acidic and Rich in Cysteine in Prostate Carcinogenesis: Development of a 3D Nanostructured Bone-Like Model. Journal of Biomedical Nanotechnology, 2016, 12, 1667-1678.	1.1	5
246	Widening the spectrum of Lynch syndrome: first report of testicular seminoma attributable to MSH2 loss. Histopathology, 2020, 76, 486-489.	2.9	5
247	Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer. Journal of Clinical Medicine, 2020, 9, 3911.	2.4	5
248	Uses of DNA Methylation in Cancer Diagnosis and Risk Assessment. , 2004, , 11-26.		5
249	Promoter Demethylation Upregulates STEAP1 Gene Expression in Human Prostate Cancer: In Vitro and In Silico Analysis. Life, 2021, 11, 1251.	2.4	5
250	The modulatory role of internet-supported mindfulness-based cognitive therapy on extracellular vesicles and psychological distress in people who have had cancer: a protocol for a two-armed randomized controlled study. Trials, 2022, 23, 118.	1.6	5
251	Epigenetically-regulated miR-30a/c-5p directly target TWF1 and hamper ccRCC cell aggressiveness. Translational Research, 2022, 249, 110-127.	5.0	5
252	The Impact of [C16Pyr][Amp] on the Aggressiveness in Breast and Prostate Cancer Cell Lines. International Journal of Molecular Sciences, 2020, 21, 9584.	4.1	4

#	Article	IF	Citations
253	Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 2715.	4.1	4
254	Epigenetic Editing in Prostate Cancer: Challenges and Opportunities. Epigenetics, 2022, 17, 564-588.	2.7	4
255	Biopsy sampling and histopathological markers for diagnosis of prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 1323-1336.	2.4	3
256	Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case. Experimental and Molecular Pathology, 2018, 105, 352-356.	2.1	3
257	Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication. Cancers, 2020, 12, 3345.	3.7	3
258	Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence. Molecular Medicine, 2020, 26, 22.	4.4	3
259	Morphological and molecular heterogeneity in testicular germ cell tumors: implications for dedicated investigations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 865-866.	2.8	3
260	Overexpression of the Mitotic Checkpoint Genes BUB1 and BUBR1 is Associated with Genomic Complexity in Clear Cell Kidney Carcinomas. Analytical Cellular Pathology, 2008, 30, 389-395.	1.4	3
261	Prognostic significance of MST1R dysregulation in renal cell tumors. American Journal of Cancer Research, 2016, 6, 1799-811.	1.4	3
262	Ki67 and LSD1 Expression in Testicular Germ Cell Tumors Is Not Associated with Patient Outcome: Investigation Using a Digital Pathology Algorithm. Life, 2022, 12, 264.	2.4	3
263	DNA hypomethylation in plasma as a cancer biomarker: when less is more?. Expert Review of Molecular Diagnostics, 2014, 14, 419-422.	3.1	2
264	MST1R methylation as a diagnostic biomarker in renal cell tumors. Acta UrolÃ³gica Portuguesa, 2015, 32, 64-64.	0.1	2
265	The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 794.e17-794.e27.	1.6	2
266	Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in Renal Cell Carcinoma cell lines. Biomedicine and Pharmacotherapy, 2021, 141, 111681.	5.6	2
267	GSTP1 Hypermethylation for Prostate Cancer Detection. , 2009, , 279-288.		2
268	Epigenetic extracellular vesicle-based biomarkers for urological malignancies: is the hope worth the hype?. Epigenomics, 2021, 13, 1514-1521.	2.1	2
269	Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression. Cellular Oncology (Dordrecht), 2022, 45, 135-149.	4.4	2
270	One sample fits all: a microfluidic-assisted methodology for label-free isolation of CTCs with downstream methylation analysis of cfDNA in lung cancer. Biomaterials Science, 2022, 10, 3296-3308.	5.4	2

#	Article	IF	Citations
271	PP1 catalytic isoforms are differentially expressed and regulated in human prostate cancer. Experimental Cell Research, 2022, 418, 113282.	2.6	2
272	Identification of AIM1 as a Hypermethylation-Inactivated Tumor Suppressor Gene in HNSCC. Otolaryngology - Head and Neck Surgery, 2004, 131, P173-P174.	1.9	1
273	Quantitative methylation profiling of renal tumors and the discovery of a new generation of molecular markers. Future Oncology, 2005, 1, 197-200.	2.4	1
274	DNA Methylation Alterations as Biomarkers for Prostate Cancer. , 2016, , 275-296.		1
275	Epigenetic biomarkers in breast cancer: Preliminary results from H3K27m3 assessment in endocrine-treatment resistance. Annals of Oncology, 2017, 28, v38.	1.2	1
276	Present and future perspectives for targeting histone modifications in therapy. , 2020, , 415-457.		1
277	Deciphering RNA Methylation in Cancer. RNA Technologies, 2021, , 247-266.	0.3	1
278	Frozen in Translation: Biobanks as a Tool for Cancer Research. Journal of Intellectual Disability - Diagnosis and Treatment, 2015, 3, 51-62.	0.3	1
279	Is There a Role for Exosome-derived MicroRNAs in Detection of Renal Cell Tumors Using Urine Samples? Editorial to [European Urology Focus 2/2 (2016) 210â€“218]. European Urology Focus, 2016, 2, 654-655.	3.1	0
280	Correlative analysis of gene expression changes and PD-L1 immunoexpression in non-small cell lung cancer. Annals of Oncology, 2018, 29, x5.	1.2	0
281	MicroRNA-30a hypermethylation as biomarker in clear cell Renal Cell Carcinoma. European Urology Supplements, 2018, 17, e2531.	0.1	0
282	Evaluation of prostate cancer volatilome: An in vitro approach. Toxicology Letters, 2018, 295, S268.	0.8	0
283	MiR663a and VIM promoter methylation: a multiplex test for discriminating bladder cancer from inflammatory disease. European Urology Supplements, 2019, 18, e3085.	0.1	0
284	Metabolic reprogramming and epigenetic landscape: an interplay to renal cell carcinoma aggressiveness promotion. European Urology Supplements, 2019, 18, e3042.	0.1	0
285	â€œEpiProStateâ€• Prostate cancer detection by DNA methylation assessment in liquid biopsies. European Urology Supplements, 2019, 18, e3110.	0.1	0
286	Hydralazine, a new hope for CRPC patients?. European Urology Supplements, 2019, 18, e3141.	0.1	0
287	Is it â€œhybridâ€•or â€œintermediateâ€?â€”more than just a semantic issue in oncocytic renal cell tumors. Annals of Translational Medicine, 2019, 7, S356-S356.	1.7	0
288	Metabolic regulation in urological tumors: Interplay with epigenetics and epitranscriptomics. , 2021, , 107-145.		0

#	Article	IF	Citations
289	Cancer Mechanisms and Emerging Therapies. Pharmaceutics, 2021, 13, 1045.	4.5	0
290	Bladder Cancer Pathology. , 2014, , 1-11.		0
291	Histone Posttranslational Modifications and Chromatin Remodelers in Prostate Cancer. , 2016, , 447-465.		0
292	Bladder Cancer Pathology. , 2017, , 537-545.		0
293	RAD51B_{me} as predictive biomarker for PD-1 blockade response in non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, e15235-e15235.	1.6	0
294	Targeting chromatin remodelers in urological tumors. , 2020, , 179-213.		0
295	Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma. Journal of Personalized Medicine, 2021, 11, 1384.	2.5	0